<DOC>
	<DOCNO>NCT02274792</DOCNO>
	<brief_summary>The purpose study learn immune response etanercept produce use modified process patient plaque psoriasis .</brief_summary>
	<brief_title>Study Assess Immunogenicity Safety Etanercept Produced Using Modified Process Patients With Plaque Psoriasis</brief_title>
	<detailed_description>This multicenter , open-label , single-arm phase 4 study patient plaque psoriasis etanercept-naïve receiving methotrexate therapy . The study consist screen period 30 day , 24-week treatment period 30-day follow-up period safety . Etanercept dose follow recommend label dose patient plaque psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subject ≥ 18 year age time screen . Subject candidate systemic therapy phototherapy opinion investigator . Subject involve body surface area ( BSA ) ≥ 10 % , static physician global assessment ( sPGA ) ≥ 3 , Psoriasis Area Severity Index ( PASI ) ≥ 10 screen baseline . Subject naïve etanercept . Subject candidate treatment etanercept opinion investigator addition care physician 's intent initiate treatment etanercept , applicable . Subject able selfinject etanercept designee . Subject use methotrexate within 4weeks first dose etanercept . Subject negative test hepatitis B surface antigen , hepatitis B core antibody hepatitis C antibody . Subject known history active tuberculosis . Subject negative test tuberculosis screen Subject , female least 2 year postmenopausal history hysterectomy , bilateral salpingectomy , bilateral oophorectomy , negative serum pregnancy test ≤ 4 week start etanercept negative urine pregnancy test baseline ( day 1 ) . Subject active erythrodermic , pustular , guttate psoriasis , medication induce psoriasis , skin condition time screen visit ( e.g. , eczema ) would interfere evaluation effect investigational product psoriasis . Subject uncontrolled , clinically significant systemic disease ( e.g. , renal failure , heart failure , hypertension , pulmonary liver disease , diabetes , anemia ) . Myocardial infarction unstable angina pectoris within last year . Major chronic inflammatory disease connective tissue disease psoriasis and/or psoriatic arthritis . Multiple sclerosis demyelinate disease . Active malignancy , include evidence cutaneous basal squamous cell carcinoma melanoma , Merkel cell carcinoma , history cancer ( fully resect surgically cure cutaneous basal cell squamous cell carcinoma ) within 5 year first dose etanercept . If malignancy occur 5 year ago , documentation diseasefree state since treatment require . Known history alcoholic hepatitis immunodeficiency syndromes include human Immunodeficiency virus ( HIV ) infection . Subject active infection ( include chronic localized infection ) antiinfectives indicate within 4 week prior first dose etanercept . Subject serious infection , define require hospitalization intravenous ( IV ) antiinfectives within 8 week prior first dose etanercept . Any condition , opinion investigator , might cause study detrimental subject . Subject condition could , opinion investigator , compromise subject 's ability give write consent and/or comply study procedure , history substance abuse psychiatric condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>125 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>